Get the Stockscreener App
38.93
3.43%
1.29
Pre-market:
39.00
0.07
+0.18%
Harrow Inc stock is traded at $38.93, with a volume of 608.72K.
It is up +3.43% in the last 24 hours and up +24.74% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
See More
Previous Close:
$37.64
Open:
$38.14
24h Volume:
608.72K
Relative Volume:
0.82
Market Cap:
$1.45B
Revenue:
$272.30M
Net Income/Loss:
$-5.14M
P/E Ratio:
-238.10
EPS:
-0.1635
Net Cash Flow:
$42.76M
1W Performance:
+17.61%
1M Performance:
+24.74%
6M Performance:
-14.81%
1Y Performance:
+28.44%
1-Day Range:
$37.86
$39.76
1-Week Range:
$33.09
$39.91
52-Week Range:
$28.54
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
38.93 | 1.45B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Is Harrow, Inc. (HROW) A Good Stock To Buy Now? - Yahoo Finance
Harrow Adds Another Piece To Ophthalmology Strategy - Benzinga
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
HROW Stock Rips Higher As Traders Digest Mixed Quarter - timothysykes.com
Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), GeneDx Holdings (WGS) - The Globe and Mail
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic - GlobeNewswire
Harrow Inc. Q1 2026 Earnings: Significant EPS Miss Triggers Stock DeclineBook Value Growth - newsline.com
HARROW INC (HROW) Stock Chart - ChartMill
What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target? - Insider Monkey
Harrow Health Inc stock (US4158581094): Ophthalmology player trades below analyst targets amid secto - AD HOC NEWS
Harrow Inc. (HROW) Q1 2026 Earnings: Significant Earnings Miss Despite Positive Stock ReactionPeak Earnings Alert - newsline.com
William Blair Maintains Harrow(HROW.US) With Buy Rating - Moomoo
Harrow Health Releases June 2026 Investor Presentation Update - TipRanks
Harrow files Regulation FD disclosure to furnish June 2026 corporate presentation - TradingView
Harrow (NASDAQ: HROW) posts June 2026 corporate investor presentation - Stock Titan
Top 5 Small Cap Stocks With Huge Growth Potential - Insider Monkey
Harrow Health earnings on deck: Can branded drugs offset California exit? - Investing.com Nigeria
Harrow Inc. Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesProfit Cycle Analysis - thelegaladvocate.com
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Harrow Inc. (HROW) Advances 2.79% as Stock Approaches Key ResistanceLow Vol ETF - thelegaladvocate.com
Harrow Inc. (HROW) Q1 2026 Earnings: Wider-than-Expected Loss Triggers Stock RallyRevenue Per Share - thelegaladvocate.com
Harrow Inc. Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock Rises Despite LossesEarnings Revision Report - newsline.com
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference - GlobeNewswire
HROW Q1 2026 Earnings: EPS Misses Estimates Significantly as Company Navigates Operational ChallengesCapex Guidance - newsline.com
Harrow (HROW) Is Up 6.8% After Reaffirming 2026 Revenue Outlook Despite Wider Q1 LossesWhat's Changed - simplywall.st
Harrow Inc. (HROW) Q1 2026 Earnings: Significant EPS Miss Amid Operational ChallengesOperating Margin Analysis - newsline.com
Harrow Inc. Q1 2026 Earnings: Pharmaceutical Firm Misses EPS Estimates by Wide MarginAnalyst Coverage Count - thelegaladvocate.com
Harrow Inc (HROW) Shares Surge 6.8% -- What GF Score of 82 Tells Investors - GuruFocus
Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism - Insider Monkey
Harrow: Demand Keeps It Interesting, Valuation Keeps It A Hold - Seeking Alpha
Harrow, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HROW) 2026-05-19 - Seeking Alpha
Harrow director Lauren Silvernail buys $31,000 in company stock By Investing.com - Investing.com Nigeria
Harrow director Adrienne Graves buys $31,070 in company stock By Investing.com - Investing.com Nigeria
Harrow director Lauren Silvernail buys $31,000 in company stock - Investing.com India
Insider Buying: Adrienne Graves Acquires Shares of Harrow Inc (H - GuruFocus
5 Best Small Cap Pharma Stocks to Buy Right Now - Insider Monkey
Harrow director Adrienne Graves buys $31,070 in company stock - Investing.com
Harrow (HROW) director Adrienne Graves buys 1,000 shares at $31.07 - Stock Titan
Harrow (HROW) director purchases 1,000 common shares at $31.00 price - Stock Titan
Harrow projects $71M-$81M Q2 revenue while reaffirming $350M-$365M 2026 outlook - MSN
[Form 4] HARROW, INC. Insider Trading Activity - Stock Titan
Mark Baum Buys Handful Of Shares In Harrow - Yahoo Finance
Harrow’s TRIESENCE Phase 3 Milestone Adds New Dimension To Growth Story - Sahm
Harrow Stock (HROW) Opinions on Q1 Earnings and Insider Buying - Quiver Quantitative
Harrow (HROW) Executives Make Notable Stock Purchases - GuruFocus
Why Harrow (HROW) Narrative Is Shifting As Analysts Recut Targets Yet Stay Positive - Yahoo Finance
Insider Buying: Mark Baum Acquires Additional Shares of Harrow I - GuruFocus
Harrow Insider Bought Shares Worth $302,000, According to a Recent SEC Filing - Moomoo
Harrow, Inc. CEO Mark L. Baum buys $302,000 in common stock - Investing.com India
Harrow president and CFO Andrew Boll buys $104,650 in stock By Investing.com - Investing.com Australia
Harrow president and CFO Andrew Boll buys $104,650 in stock - Investing.com India
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):